<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2821">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02248636</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-014-13F</org_study_id>
    <nct_id>NCT02248636</nct_id>
  </id_info>
  <brief_title>Cholinesterase Inhibitor Discontinuation</brief_title>
  <acronym>CID</acronym>
  <official_title>Cholinesterase Inhibitor Discontinuation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tries to determine if stopping certain medications that are used to treat dementia&#xD;
      will cause worsening from the patient and family perspective.&#xD;
&#xD;
      All of the participants will take pills that look identical, and that may contain active drug&#xD;
      or an inactive pill (a placebo). Half of the group will receive the same treatment they were&#xD;
      taking before the study -- this is called the &quot;sham discontinuation&quot; arm. The other half will&#xD;
      receive a reduced dose of their medication, and then an inactive pill (placebo) -- this is&#xD;
      called the &quot;real discontinuation&quot; arm.&#xD;
&#xD;
      Participants will be able to return to their previous dose of medication at any time during&#xD;
      the study. The percentage of people who return will be measured and compared. Other medical&#xD;
      events and factors such as behaviors, thinking, and caregiver distress, will be measured and&#xD;
      compared between the groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are no reliable findings from controlled trials about discontinuation of cholinesterase&#xD;
      inhibitors from a patient and family perspective. It is unknown at what point these&#xD;
      medications do not have effects, and how they can safely be discontinued.&#xD;
&#xD;
      The investigators will identify Veterans who have been taking a cholinesterase inhibitor (CI)&#xD;
      (donepezil or galantamine) for at least one year. After informed consent, the investigators&#xD;
      will randomize them to Real Taper (half-dose of the CI they had taken for 3 weeks, then&#xD;
      placebo for 3 weeks), or Sham Taper (continued full dose of the CI they had taken for 6&#xD;
      weeks). The pills will be blinded by over-encapsulating of the drug or placebo.&#xD;
&#xD;
      An intake interview will ascertain history and measure behaviors, cognitive symptoms, and&#xD;
      mood, as well as caregiver burden. Phone calls will assess treatment use and adverse events&#xD;
      at week 2 and week 4. An exit interview at week 6 will measure the same variables as at&#xD;
      baseline. Participants will be unblinded at that point so they will know which treatment had&#xD;
      been used. A follow-up call at 12 weeks will ascertain ongoing treatment and any further&#xD;
      adverse events.&#xD;
&#xD;
      At any point in the study, participants and caregivers will be able to return to their&#xD;
      pre-study dose of medication.&#xD;
&#xD;
      The primary outcome is the percentage of participants who successfully complete a 6-week&#xD;
      discontinuation. This will be compared between arms. Other outcomes related to medical events&#xD;
      (e.g. hospitalizations, falls), symptoms (e.g. cognition, behaviors), and caregiver distress&#xD;
      will be measured and compared.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 22, 2015</start_date>
  <completion_date type="Actual">October 1, 2019</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful Completion</measure>
    <time_frame>6 weeks</time_frame>
    <description>Participants can return to their pre-study dose of medication at any time. If they complete 6 weeks of either real discontinuation or sham discontinuation, they are considered to have successfully completed treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Caregiver Burden</measure>
    <time_frame>6 weeks</time_frame>
    <description>The Zarit Caregiver Burden Interview contains 22 items, each on a 5-point scale, for a maximum score of 110. The minimum score is 0. A higher score indicates worse subjective burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Veteran Cognition</measure>
    <time_frame>6 weeks</time_frame>
    <description>Six-Item Screener is a telephone-based assessment of cognitive status. The score ranges from 0 to 6. A higher score indicates better cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Veteran Functioning</measure>
    <time_frame>6 weeks</time_frame>
    <description>The Alzheimer's Disease Cooperative Study ADL Scale (ADCS-ADL) is a 23-item scale divided into activities of daily living and independent activities of daily living. Scores range from 0-78. A lower score indicates worse functional ability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavioral Symptoms</measure>
    <time_frame>6 weeks</time_frame>
    <description>The Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) is a 25-item instrument. Scores range from 0-75, with a higher number indicating worse behavioral symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-study Treatment Choice</measure>
    <time_frame>12 weeks</time_frame>
    <description>Veteran and caregiver decision to continue, or to have restarted, the pre-study medication at 12 weeks. The participants were unblinded at 6 weeks, and were requested to make their own decision about restarting.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Real discontinuation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group is tapered off their previous cholinesterase inhibitor medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham discontinuation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>This group receives their previous cholinesterase inhibitor medication, but in in placebo form.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholinesterase inhibitor</intervention_name>
    <description>This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.</description>
    <arm_group_label>Real discontinuation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham discontinuation</intervention_name>
    <description>This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form</description>
    <arm_group_label>Sham discontinuation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females ages 60 and older.&#xD;
&#xD;
          -  Taking stable dose of donepezil 10mg or greater per day, or galantamine 8mg or greater&#xD;
             per day, for at least 1 year.&#xD;
&#xD;
          -  Presence of a primary caregiver who can assume responsibility for medication&#xD;
             compliance, OR residence in a nursing home with a staff member who can provide&#xD;
             information.&#xD;
&#xD;
          -  Primary care visit within last 12 months.&#xD;
&#xD;
          -  Willing to have the CI medication discontinued.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Terminal medical condition for which life expectancy would be less than 6 months.&#xD;
&#xD;
          -  Parkinson's Disease&#xD;
&#xD;
          -  Presence of any uncontrolled systemic illness that would interfere with participation&#xD;
             in the study.&#xD;
&#xD;
          -  Unstable medical condition.&#xD;
&#xD;
          -  Receiving services from hospice.&#xD;
&#xD;
          -  Current prescription with more than one CI&#xD;
&#xD;
          -  Receiving medication in an investigational drug study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen M Thielke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Puget Sound Health Care System Seattle Division, Seattle, WA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205-5484</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boise VA Medical Center, Boise, ID</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA</name>
      <address>
        <city>Bedford</city>
        <state>Massachusetts</state>
        <zip>01730</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System Seattle Division, Seattle, WA</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 22, 2014</study_first_submitted>
  <study_first_submitted_qc>September 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <results_first_submitted>September 29, 2020</results_first_submitted>
  <results_first_submitted_qc>September 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 23, 2020</results_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Cholinesterase inhibitor</keyword>
  <keyword>Discontinuation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholinesterase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT02248636/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 8, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT02248636/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Veterans who have received a prescription for a cholinesterase inhibitor for one year or greater.</recruitment_details>
      <pre_assignment_details>72 people were enrolled and consented, but only 61 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Real Discontinuation</title>
          <description>This group is tapered off their previous cholinesterase inhibitor medication.&#xD;
Cholinesterase inhibitor: This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.</description>
        </group>
        <group group_id="P2">
          <title>Sham Discontinuation</title>
          <description>This group receives their previous cholinesterase inhibitor medication, but in in placebo form.&#xD;
Sham discontinuation: This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Real Discontinuation</title>
          <description>This group is tapered off their previous cholinesterase inhibitor medication.&#xD;
Cholinesterase inhibitor: This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.</description>
        </group>
        <group group_id="B2">
          <title>Sham Discontinuation</title>
          <description>This group receives their previous cholinesterase inhibitor medication, but in in placebo form.&#xD;
Sham discontinuation: This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.34" spread="10.48"/>
                    <measurement group_id="B2" value="77.94" spread="9.72"/>
                    <measurement group_id="B3" value="77.69" spread="9.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Successful Completion</title>
        <description>Participants can return to their pre-study dose of medication at any time. If they complete 6 weeks of either real discontinuation or sham discontinuation, they are considered to have successfully completed treatment.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Real Discontinuation</title>
            <description>This group is tapered off their previous cholinesterase inhibitor medication.&#xD;
Cholinesterase inhibitor: This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.</description>
          </group>
          <group group_id="O2">
            <title>Sham Discontinuation</title>
            <description>This group receives their previous cholinesterase inhibitor medication, but in in placebo form.&#xD;
Sham discontinuation: This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form</description>
          </group>
        </group_list>
        <measure>
          <title>Successful Completion</title>
          <description>Participants can return to their pre-study dose of medication at any time. If they complete 6 weeks of either real discontinuation or sham discontinuation, they are considered to have successfully completed treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Caregiver Burden</title>
        <description>The Zarit Caregiver Burden Interview contains 22 items, each on a 5-point scale, for a maximum score of 110. The minimum score is 0. A higher score indicates worse subjective burden.</description>
        <time_frame>6 weeks</time_frame>
        <population>Not all of the caregivers completed the instrument. Some were unavailable after study enrollment. Some had a change in caregiver. Some refused to respond to all of the questions, since the instrument is rather lengthy.</population>
        <group_list>
          <group group_id="O1">
            <title>Real Discontinuation</title>
            <description>This group is tapered off their previous cholinesterase inhibitor medication.&#xD;
Cholinesterase inhibitor: This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.</description>
          </group>
          <group group_id="O2">
            <title>Sham Discontinuation</title>
            <description>This group receives their previous cholinesterase inhibitor medication, but in in placebo form.&#xD;
Sham discontinuation: This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form</description>
          </group>
        </group_list>
        <measure>
          <title>Caregiver Burden</title>
          <description>The Zarit Caregiver Burden Interview contains 22 items, each on a 5-point scale, for a maximum score of 110. The minimum score is 0. A higher score indicates worse subjective burden.</description>
          <population>Not all of the caregivers completed the instrument. Some were unavailable after study enrollment. Some had a change in caregiver. Some refused to respond to all of the questions, since the instrument is rather lengthy.</population>
          <units>Change in Zarit score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.58" spread="11.13"/>
                    <measurement group_id="O2" value="1.66" spread="17.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Veteran Cognition</title>
        <description>Six-Item Screener is a telephone-based assessment of cognitive status. The score ranges from 0 to 6. A higher score indicates better cognition.</description>
        <time_frame>6 weeks</time_frame>
        <population>Some of the participants refused to complete the cognitive instrument over the phone.</population>
        <group_list>
          <group group_id="O1">
            <title>Real Discontinuation</title>
            <description>This group is tapered off their previous cholinesterase inhibitor medication.&#xD;
Cholinesterase inhibitor: This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.</description>
          </group>
          <group group_id="O2">
            <title>Sham Discontinuation</title>
            <description>This group receives their previous cholinesterase inhibitor medication, but in in placebo form.&#xD;
Sham discontinuation: This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form</description>
          </group>
        </group_list>
        <measure>
          <title>Veteran Cognition</title>
          <description>Six-Item Screener is a telephone-based assessment of cognitive status. The score ranges from 0 to 6. A higher score indicates better cognition.</description>
          <population>Some of the participants refused to complete the cognitive instrument over the phone.</population>
          <units>Change in Six-Item Screener Score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="2.13"/>
                    <measurement group_id="O2" value="0.13" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Veteran Functioning</title>
        <description>The Alzheimer's Disease Cooperative Study ADL Scale (ADCS-ADL) is a 23-item scale divided into activities of daily living and independent activities of daily living. Scores range from 0-78. A lower score indicates worse functional ability.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Real Discontinuation</title>
            <description>This group is tapered off their previous cholinesterase inhibitor medication.&#xD;
Cholinesterase inhibitor: This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.</description>
          </group>
          <group group_id="O2">
            <title>Sham Discontinuation</title>
            <description>This group receives their previous cholinesterase inhibitor medication, but in in placebo form.&#xD;
Sham discontinuation: This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form</description>
          </group>
        </group_list>
        <measure>
          <title>Veteran Functioning</title>
          <description>The Alzheimer's Disease Cooperative Study ADL Scale (ADCS-ADL) is a 23-item scale divided into activities of daily living and independent activities of daily living. Scores range from 0-78. A lower score indicates worse functional ability.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" spread="11.87"/>
                    <measurement group_id="O2" value="-0.59" spread="6.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Behavioral Symptoms</title>
        <description>The Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) is a 25-item instrument. Scores range from 0-75, with a higher number indicating worse behavioral symptoms.</description>
        <time_frame>6 weeks</time_frame>
        <population>Not all caregivers were willing to respond to all the items.</population>
        <group_list>
          <group group_id="O1">
            <title>Real Discontinuation</title>
            <description>This group is tapered off their previous cholinesterase inhibitor medication.&#xD;
Cholinesterase inhibitor: This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.</description>
          </group>
          <group group_id="O2">
            <title>Sham Discontinuation</title>
            <description>This group receives their previous cholinesterase inhibitor medication, but in in placebo form.&#xD;
Sham discontinuation: This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form</description>
          </group>
        </group_list>
        <measure>
          <title>Behavioral Symptoms</title>
          <description>The Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) is a 25-item instrument. Scores range from 0-75, with a higher number indicating worse behavioral symptoms.</description>
          <population>Not all caregivers were willing to respond to all the items.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="6.26"/>
                    <measurement group_id="O2" value="-1.23" spread="3.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-study Treatment Choice</title>
        <description>Veteran and caregiver decision to continue, or to have restarted, the pre-study medication at 12 weeks. The participants were unblinded at 6 weeks, and were requested to make their own decision about restarting.</description>
        <time_frame>12 weeks</time_frame>
        <population>We were unable to reach some participants at 12 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Real Discontinuation</title>
            <description>This group is tapered off their previous cholinesterase inhibitor medication.&#xD;
Cholinesterase inhibitor: This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.</description>
          </group>
          <group group_id="O2">
            <title>Sham Discontinuation</title>
            <description>This group receives their previous cholinesterase inhibitor medication, but in in placebo form.&#xD;
Sham discontinuation: This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form</description>
          </group>
        </group_list>
        <measure>
          <title>Post-study Treatment Choice</title>
          <description>Veteran and caregiver decision to continue, or to have restarted, the pre-study medication at 12 weeks. The participants were unblinded at 6 weeks, and were requested to make their own decision about restarting.</description>
          <population>We were unable to reach some participants at 12 weeks.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants taking pre-study medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants not taking pre-study medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Six weeks.</time_frame>
      <desc>Dementia patients have a variety of behavioral and health events, which may fluctuate over time. We considered adverse events to be novel medical events differing from baseline.</desc>
      <group_list>
        <group group_id="E1">
          <title>Real Discontinuation</title>
          <description>This group is tapered off their previous cholinesterase inhibitor medication.&#xD;
Cholinesterase inhibitor: This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.</description>
        </group>
        <group group_id="E2">
          <title>Sham Discontinuation</title>
          <description>This group receives their previous cholinesterase inhibitor medication, but in in placebo form.&#xD;
Sham discontinuation: This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Behavior</sub_title>
                <description>Behavior changed significantly</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was designed to allow participants to stop the study medication at any time, and for any reason. This is different than administrative withdrawal.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>William Banks, Associate Chief of Staff for Research</name_or_title>
      <organization>Puget Sound VA</organization>
      <phone>206 764-2701</phone>
      <email>william.banks4@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

